The Winding Journey of Biotech Capital Raising: Deciphering the Jargon
Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists’ mindsets and investment theses will increase the probability of securing needed capital.
The Winding Road of Biotech Capital Raising: Deciphering the Jargon
Published in Trends In Biotechnology
Authors: Nicholas Frame, Michael Casasanta, and Oded Ben-Joseph
Abstract:
Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists’ mindsets and investment theses will increase the probability of securing needed capital.
News
Leaders of Life Sciences – How Leadership Must Evolve As Companies Scale
In this conversation, Stan Glazer, Managing Director at Outcome, shares insights from his extensive experience in the life sciences industry.
Read MoreResources
Outcome Capital Life Science Market Pulse, April 2025
Outcome Capital Life Science Market Pulse April 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
